Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning
Top Cited Papers
Open Access
- 11 January 2019
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 53 (3), 1800986
- https://doi.org/10.1183/13993003.00986-2018
Abstract
Epidermal Growth Factor Receptor (EGFR) genotyping is critical for treatment guideline such as the use of tyrosine kinase inhibitors in lung adenocarcinoma (LA). Conventional identification of EGFR genotype requires biopsy and sequence testing that is invasive and may suffer from the difficulty in accessing tissue samples. Here, we proposed a deep learning (DL) model to predict the EGFR mutation status in LA by non-invasive computed tomography (CT). We retrospectively collected 844 LA patients with preoperative CT image, EGFR mutation and clinical information from two hospitals. An end-to-end DL model was proposed to predict the EGFR mutation status by CT scanning. By training in 14926 CT images, the DL model achieved encouraging predictive performance in both the primary cohort (n=603; AUC=0.85, 95% CI 0.83–0.88) and the independent validation cohort (n=241; AUC=0.81, 95% CI 0.79–0.83), which showed significant improvement than previous studies using hand-crafted CT features or clinical characteristics (p<0.001). The deep learning score demonstrated significant difference in EGFR-mutant and EGFR-wild type tumours (p<0.001). Since CT is routinely used in lung cancer diagnosis, the DL model provides a non-invasive and easy-to-use method for EGFR mutation status prediction.Funding Information
- Instrument Developing Project of the Chinese Academy of Sciences (YZ201502)
- National Key R&D Program of China (2016YFC010380, 2017YFA0205200, 2017YFC1308700, 2017YFC1308701, 2017YFC1309100)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- National Natural Science Foundation of China (61231004, 81227901, 81501616, 81527805, 81671851, 81771924)
- Beijing Municipal Science and Technology Commission (Z161100002616022, Z171100000117023)
- National Institute of Biomedical Imaging and Bioengineering (R01EB020527)
This publication has 37 references indexed in Scilit:
- Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approachNature Communications, 2014
- Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and MutationsRadiology, 2014
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future TherapiesJournal of Clinical Oncology, 2013
- Non–Small Cell Lung Cancer: Identifying Prognostic Imaging Biomarkers by Leveraging Public Gene Expression Microarray Data—Methods and Preliminary ResultsRadiology, 2012
- Seeding of tumour cells following breast biopsy: a literature reviewThe British Journal of Radiology, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinomaEuropean Respiratory Journal, 2011
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary AdenocarcinomaJournal of Thoracic Oncology, 2006